
The potential clinical benefits of Fresenius improved dialysate include:
- Less frequent and severe hypoglycemic episodes 1
- Lower amounts of glucose lost in effluent dialysate 1
- Less fatigue 5
- Helps prevent vascular calcification in hemodialysis patients 3,4
- Less intradialytic hypotension 3,4
- Potentially lower mortality risk 6
References:
1 Burmeister JE, Scapini A, da Rosa MD, da Costa MG, Campos BM (2007). Glucose-added dialysis fluid prevents asymptomatic hypoglycemia in regular haemodialysis. Nephrol Dial Transplant 22:1184-1189.
2 Ishimura, E., et al. (2007). Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clinical Nephrology, 68(4),222-227.
3 Elsharkawy, M., et al (2006). Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates. Hemodialysis International, 10, S16-S23.
4 Navarro-Gonzalez,, J., Mora-Fernandez, C., & Garcia-Perez, J. (2009). Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Seminars in Dialysis, 22(1), 37-44.
5 Raimann, J, et al (2009, November). Fatigue in chronic hemodialysis patients: results from a prospective, randomized, cross-over trial of 200 mg/dL and 100 mg/dL dialysate dextrose concentrations. Poster presentation at 2009 ASN, San Diego, CA.
6 Lacson, E., et al (2009, November). Magnesium and mortality risk in hemodialysis patients. Poster presentation at 2009 ASN, San Diego, CA. Paper submitted for publication.

